Health Care & Life Sciences » Biotechnology | SIGA Technologies Inc.

SIGA Technologies Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
17,177.30
265,463.10
39,451.30
39,698.00
36,235.50
421,807.80
Depreciation, Depletion & Amortization
463.10
351.60
247.40
174.30
132.20
69.60
Other Funds
155.30
415.90
15.50
428.00
591.10
346,596.60
Funds from Operations
23,499.20
263,304.00
37,376.20
34,279.70
16,494.40
65,979.40
Changes in Working Capital
81,935.70
277,480.50
48,485.60
81,311.10
8,336.10
2,891.90
Net Operating Cash Flow
58,436.50
14,176.50
11,109.40
115,590.80
8,158.30
68,871.30
Capital Expenditures
857.30
28.00
109.00
23.90
100.10
Sale of Fixed Assets & Businesses
-
569.60
-
-
-
Net Investing Cash Flow
857.30
541.60
109.00
1,188.70
100.10
Issuance/Reduction of Debt, Net
1,000.00
2,000.00
2,000.00
-
-
Net Financing Cash Flow
1,713.10
2,313.90
2,003.30
30,392.90
585.60
Net Change in Cash
59,292.30
12,404.20
8,997.10
84,009.20
8,844.00
Free Cash Flow
57,579.20
14,148.50
11,000.40
115,614.70
8,258.40
Deferred Taxes & Investment Tax Credit
9,599.90
-
-
20.40
2,718.00
9,301.40
Other Sources
-
-
-
1,212.60
-
Change in Capital Stock
2,868.40
102.00
12.20
34,596.50
5.50

About SIGA Technologies

View Profile
Address
31 East 62nd Street
New York New York 10065
United States
Employees -
Website http://www.siga.com
Updated 07/08/2019
SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand.